Ontology highlight
ABSTRACT:
Conclusions: In this review, we will address combined anti-cancer therapeutic strategies described so far which involve the use of CX-4945. Data from preclinical studies clearly show the ability of CX-4945 to synergistically cooperate with different classes of anti-neoplastic agents, thereby contributing to an orchestrated anti-tumour action against multiple targets. Overall, these promising outcomes support the translation of CX-4945 combined therapies into clinical anti-cancer applications.
SUBMITTER: D'Amore C
PROVIDER: S-EPMC7717057 | biostudies-literature | 2020 Dec
REPOSITORIES: biostudies-literature
D'Amore Claudio C Borgo Christian C Sarno Stefania S Salvi Mauro M
Cellular oncology (Dordrecht, Netherlands) 20201014 6
<h4>Background</h4>Protein kinase CK2 inhibition has long been considered as an attractive anti-cancer strategy based on the following considerations: CK2 is a pro-survival kinase, it is frequently over-expressed in human tumours and its over-expression correlates with a worse prognosis. Preclinical evidence strongly supports the feasibility of this target and, although dozens of CK2 inhibitors have been described in the literature so far, CX-4945 (silmitasertib) was the first that entered into ...[more]